Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that in 2014, sales of drugs from multinational corporations will represent 92 percent of Mexico's non-small-cell lung cancer drug market. Factors promoting the market's growth include a modest increase in the use of premium-priced chemotherapies and targeted agents, brand loyalty among prescribing oncologists and an increase in diagnosed incident cases.

"Our research shows that Mexican physicians in the private sector retain high brand loyalty to drugs used to treat non-small-cell lung cancer. For example, Bristol-Myers Squibb's Bristaxol, for which paclitaxel generics have been available for several years in Mexico, still enjoys almost 80 percent use," stated Decision Resources' Analyst Amy Duval, M.Res.

The new Emerging Markets report entitled Non-Small-Cell Lung Cancer in Mexico also finds that during the 2009 - 2014 forecast period, two therapies are expected to be approved for the indication: Merck KGaA's Erbitux in 2011 and Bayer's Nexavar in 2013. Erbitux is already used off-label for non-small-cell lung cancer in Mexico because of its endorsement in the National Comprehensive Cancer Network (NCCN) guidelines for certain patients.

Interviewed and surveyed oncologists confirmed their use of the NCCN guidelines to treat non-small-cell lung cancer in Mexico. In fact, according to one oncologist, even the Mexican Society of Oncology has its own Spanish edition of the NCCN guidelines.

The new report contains extensive primary research of physicians and epidemiology study in cities across Mexico, including Mexico City and Guadalajara.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Christopher Comfort   Decision Resources   781-296-2597   ccomfort@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort, Decision Resources, +1-781-296-2597,
ccomfort@dresources.com

In the Rheumatoid Arthritis Drug Market, the Uptake of Alternative Biologics Such as Roche/Chugai's Actemra/RoActemra Will Erode the Market Share of TNF-Alpha Inhibitors Through 2019

View Now